期刊文献+

What's hot in inflammatory bowel disease in 2011? 被引量:1

What's hot in inflammatory bowel disease in 2011?
下载PDF
导出
摘要 Ulcerative colitis and Crohn's disease(CD) are the two major forms of inflammatory bowel disease(IBD).In this highlight topic series of articles,the most recent advances in the IBD field are reviewed,especially the newly described cytokines,including the therapeutic implications for their manipulation.In addition,the interplay between the intestinal microbiota and the host is reviewed,including the role of defensins and dysbiosis in CD pathogenesis.Finally,the importance of the non immune systems such as endothelial cells and the hemostatic system are highlighted as new players in IBD pathogenesis. Ulcerative colitis and Crohn's disease (CD) are the two major forms of inflammatory bowel disease (IBD). In this highlight topic series of articles, the most recent advances in the IBD field are reviewed, especially the newly described cytokines, including the therapeutic implications for their manipulation. In addition, the in- terplay between the intestinal microbiota and the host is reviewed, including the role of defensins and dysbiosis in CD pathogenesis. Finally, the importance of the non immune systems such as endothelial cells and the he- mostatic system are highlighted as new players in IBD pathogenesis.
作者 Silvio Danese
机构地区 IBD Center
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第5期545-546,共2页 世界胃肠病学杂志(英文版)
关键词 溃疡性结肠炎 炎症 血管内皮细胞 发病机制 IBD 细胞因子 肠道菌群 免疫系统 Crohn's disease Ulcerative colitis Inflam-matory bowel disease Immunology, Pathogenesis
  • 相关文献

参考文献5

二级参考文献229

  • 1Petros Zezos,Georgia Papaioannou,Nikolaos Nikolaidis,Themistoclis Vasiliadis,Olga Giouleme,Nikolaos Evgenidis.Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation[J].World Journal of Gastroenterology,2005,11(48):7639-7645. 被引量:4
  • 2Silvio Danese,Claudio Fiocchi.Etiopathogenesis of inflammatory bowel diseases[J].World Journal of Gastroenterology,2006,12(30):4807-4812. 被引量:61
  • 3Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-1197.
  • 4Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147:258-267.
  • 5Armstrong AM, Gardiner KR, Kirk SJ, Halliday MI, Rowlands BJ. Tumour necrosis factor and inflammatory bowel disease. Br J Surg 1997; 84:1051-1058.
  • 6Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8:171-178.
  • 7Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005; 206:296-305.
  • 8Hvas CL, Kelsen J, Agnholt J, Hollsberg P, Tvede M, Moller JK, Dahlerup JF. Crohn's disease intestinal CD4+ T cells have impaired interleukin-10 production which is not restored by probiotic bacteria. Scand J Gastroentero12007; 42:592-601.
  • 9Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, Papadakis KA. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol 2007; 125:281-290.
  • 10Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S. Type I T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol1997; 150:823-832.

共引文献76

同被引文献22

  • 1Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium diffi- cile on inflammatory bowel disease [ J]. Clin Gastroenterol Hepatol, 2007, 5(3): 345-351.
  • 2Rodemann JF, Dubberke ER, Reske KA, et aL Incidence of Clostridi- um difficile infection in inflammatory bowel disease [ J]. Clin Gastro- enterol Hepatol, 2007, 5 (3) : 339-344.
  • 3Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisa- tion burden associated with Clostridium difficile in patients with inflam- matory bowel disease [J]. Gut, 2008, 57(2) : 205-210.
  • 4Burke KE, Lamont JT. Clostridium difficile inection: a worldwide dis- ease [J]. Gut Liver, 2014, 8(1): 1-6.
  • 5Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative co-litis [J]. Aliment Pharmacol Ther, 2012, 36(11-12) : 1032-1039.
  • 6Kelly CP. A 76-year-old man with recurrent Clostridium difficile-asso- eiated diarrhea: review of C. difficile infection[J], JAMA, 2009, 301(9) : 954-962.
  • 7Sehneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in pa- tients with inflammatory bowel disease and the risk of serious bacterial infections [ J]. Aliment Pharmacol T- her, 2009, 30(3) : 253-264.
  • 8Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inflammatory bowel disease therapy [ J]. Inflamm Bowel Dis, 2014, 20(1) : 196-212.
  • 9Mir SA, Kellermayer R. Clostridium difficile infection in newly diag- nosed pediatric inflammatory bowel disease in the mid- southern United States [J]. J Pediatr Gastroenterol Nutr, 2013, 57(4) : 487-488.
  • 10Ananthakrishnan AN, McGinley EL. Infection-related hospitaliza- tions are associated with increased mortality in patients with in- flam- matory bowel diseases [ J 1. J Crohns Colitis, 2013, 7 ( 2 ) : 107-112.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部